Literature DB >> 12055239

The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.

Reinhold Schirmbeck1, Detlef Stober, Shereen El-Kholy, Petra Riedl, Jörg Reimann.   

Abstract

MHC-I-restricted CTL responses of H-2(d) (L(d+) or L(d-)) and F(1) H-2(dxb) mice to hepatitis B surface Ag (HBsAg) are primed by either DNA vaccines or HBsAg particles. The D(d)/S(201-209) and K(d)/S(199-208) epitopes are generated by processing endogenous HBsAg; the K(b)/S(208-215) epitope is generated by processing exogenous HBsAg; and the L(d)/S(28-39) epitope is generated by exogenous as well as endogenous processing of HBsAg. DNA vaccination primed high numbers of CTL specific for the L(d)/S(28-39) HBsAg epitope, low numbers of CTL specific for the D(d)/S(201-209) or K(d)/S(199-208) HBsAg epitopes in BALB/c mice, and high numbers of D(d)/S(201-209)- and K(d)/S(199-208)-specific CTL in congenic H-2(d)/L(d-) dm2 mice. In F(1)(dxb) mice, the K(d)-, D(d)-, and K(b)-restricted CTL responses to HBsAg were strikingly suppressed in the presence but efficiently elicited in the absence of L(d)/S(28-39)-specific CTL. Once primed, the K(d)- and D(d)-restricted CTL responses to HBsAg were resistant to suppression by immunodominant L(d)/S(28-39)-specific CTL. The L(d)-restricted immunodominant CTL reactivity to HBsAg can thus suppress priming to multiple alternative epitopes of HBsAg, independent of the processing pathway that generates the epitope, of the background of the mouse strain used, and of the presence/absence of different allelic variants of the K and D MHC class I molecules.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055239     DOI: 10.4049/jimmunol.168.12.6253

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.

Authors:  Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2003-12-02       Impact factor: 4.599

2.  Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Authors:  Andrés Báez-Astúa; Elsa Herráez-Hernández; Natalio Garbi; Hilda A Pasolli; Victoria Juárez; Harald Zur Hausen; Angel Cid-Arregui
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  CD8 T cell competition for dendritic cells in vivo is an early event in activation.

Authors:  Richard A Willis; John W Kappler; Philippa C Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

4.  TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

Authors:  Marcin Cebula; Mathias Riehn; Upneet Hillebrand; Ramona F Kratzer; Florian Kreppel; Georgia Koutsoumpli; Toos Daemen; Hansjörg Hauser; Dagmar Wirth
Journal:  Mol Ther       Date:  2017-07-14       Impact factor: 11.454

5.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

6.  Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.

Authors:  Wai-Ping Woo; Tracy Doan; Karen A Herd; Hans-Jürgen Netter; Robert W Tindle
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells.

Authors:  Shuang Geng; Yiwei Zhong; Shuang Wang; Hu Liu; Qiang Zou; Xiaoping Xie; Chaofan Li; Qingling Yu; Zhonghuai He; Bin Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.